Dr. Martens

Dr. Martens plc is the British iconic boot maker and lifestyle brand listed on the London Stock Exchange under DOCS following its January 2021 initial public offering, which valued the company at approximately £3.7 billion at listing. Permira, the European private equity firm that acquired Dr. Martens in 2013 for £300 million, remains the largest shareholder following partial exits through the IPO and subsequent share sales. The brand entered a defined turnaround phase in 2024-2025 under new leadership.

Founded around the air-cushioned sole technology developed by German doctor Klaus Märtens in 1947 and licensed to UK shoemakers R. Griggs Group in Wollaston, Northamptonshire in 1959, the brand produced its first 1460 eight-eyelet boot on 1 April 1960 (the date that gave the model its name). The boot became culturally definitive across British subcultures from the late 1960s onward, anchoring punk, skinhead, mod, and grunge movements before its progressive mainstream and luxury-adjacent positioning through the 2010s and 2020s. Dr. Martens reported revenue of approximately £787 million in fiscal year 2024 (ended 31 March 2024), down 12% year-over-year, with continued declines into fiscal 2025 amid US wholesale weakness and weaker consumer demand. CEO Kenny Wilson stepped down in November 2024 following multiple profit warnings, with Ije Nwokorie (previously the company’s Chief Brand Officer) appointed CEO effective January 2025 to lead the operational turnaround. The recovery plan emphasizes US market stabilization, brand-marketing investment, the rationalization of underperforming wholesale relationships, and a renewed focus on the brand’s iconic core 1460, 1461, and 2976 Chelsea boot product lines alongside selective newness. The brand suspended Russian operations in 2022.

Dr. Martens operates approximately 240 directly operated stores globally, with the strongest concentrations in the United States, the United Kingdom, Germany, France, Japan, China, South Korea, and Australia. Distribution is supplemented by extensive wholesale placement in athletic-and-lifestyle specialty retailers, department store concessions, and select multi-brand footwear specialty stores across more than 60 countries. The typical Dr. Martens store occupies 100 to 250 square meters, with formats emphasizing the brand’s industrial heritage, in-store boot customization stations at flagship locations, and a clear segmentation between core heritage product and seasonal collaboration ranges. For mall operators, Dr. Martens is a Class A specialty footwear tenant for regional and super-regional centers, typically positioned in the lifestyle-and-streetwear cluster alongside Vans, Converse, New Balance, and similar heritage-meets-fashion footwear brands. The current turnaround period has prompted selective store closures rather than aggressive expansion, with landlords negotiating with the brand around lease renegotiations and footprint optimization rather than new-opening commitments.